Shukra Pharmaceuticals Limited

BSE:524632 Stock Report

Market Cap: ₹8.1b

Shukra Pharmaceuticals Past Earnings Performance

Past criteria checks 5/6

Shukra Pharmaceuticals has been growing earnings at an average annual rate of 78.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 46.4% per year. Shukra Pharmaceuticals's return on equity is 26.6%, and it has net margins of 35%.

Key information

78.5%

Earnings growth rate

55.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate46.4%
Return on equity26.6%
Net Margin35.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shukra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524632 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24413144830
30 Jun 24605186570
31 Mar 24765185820
31 Dec 231,117185580
30 Sep 2394891560
30 Jun 2374345490
31 Mar 2359544540
31 Dec 2221811590
30 Sep 2224811590
30 Jun 2223910520
31 Mar 222058550
31 Dec 211310540
30 Sep 211441520
30 Jun 211301450
31 Mar 211122450
31 Dec 20110-1430
30 Sep 201211420
30 Jun 201191430
31 Mar 201180490
31 Dec 191048370
30 Sep 19634270
30 Jun 19574220
31 Mar 19575220
31 Dec 1840-5210
30 Sep 18625190
30 Jun 185410150
31 Mar 18535160
31 Dec 176312130
30 Sep 17443130
30 Jun 17527120
31 Mar 17515120
31 Dec 16543110
30 Sep 16451110
30 Jun 16502110
31 Mar 16481120
31 Dec 15193160
30 Sep 15196160
30 Jun 15222110
31 Mar 15261120
31 Dec 14407110
30 Sep 14482100
30 Jun 1446-290
31 Mar 1444-8120

Quality Earnings: 524632 has high quality earnings.

Growing Profit Margin: 524632's current net profit margins (35%) are higher than last year (9.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524632's earnings have grown significantly by 78.5% per year over the past 5 years.

Accelerating Growth: 524632's earnings growth over the past year (58%) is below its 5-year average (78.5% per year).

Earnings vs Industry: 524632 earnings growth over the past year (58%) exceeded the Pharmaceuticals industry 20.5%.

Return on Equity

High ROE: 524632's Return on Equity (26.6%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 20:38
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shukra Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution